November 24, 2017 09:13 AM EST
Editor's note

The 10 most pop­u­lar sto­ries in End­points News — so far in 2017

John Carroll

Editor & Founder

Since Ar­salan Arif and I ramped up the main edi­tion of End­points News 16 months ago, we’ve pub­lished more than a mil­lion words on bio­phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bris­tol My­ers launch­es fresh round of ma­jor cost cuts in bid to get ahead of patent cliff

As­traZeneca takes $753M charge on aban­doned com­ple­ment drug from Alex­ion deal

Pfiz­er hires No­var­tis on­col­o­gy ex­ec to steer its can­cer am­bi­tions

Up­dat­ed: Lil­ly posts 45% sales jump, culls four pro­grams across obe­si­ty, Alzheimer's, heart fail­ure and eczema

As­traZeneca of­fers some de­tail on Chi­na probe, reaf­firms com­mit­ment to that mar­ket

J&J, In­tra-Cel­lu­lar quick­ly sealed $14B deal as three oth­ers passed on buy­ing the neu­ro drug­mak­er

A service from the Financial Times